-$0.18 EPS Expected for OncoSec Medical Inc (ONCS) This Quarter

Wall Street brokerages expect that OncoSec Medical Inc (NASDAQ:ONCS) will report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.24) in the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is expected to announce its next earnings results on Friday, April 19th.

According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next fiscal year, analysts expect that the business will post earnings of ($0.65) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for OncoSec Medical.

A number of research analysts have recently weighed in on ONCS shares. Zacks Investment Research raised shares of OncoSec Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Friday, March 15th. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research note on Monday, April 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $3.13.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 240,843 shares during the last quarter. Geode Capital Management LLC boosted its position in OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 163,405 shares during the last quarter. Northern Trust Corp boosted its position in OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 28,914 shares during the last quarter. Bank of New York Mellon Corp boosted its position in OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 83,150 shares during the last quarter. Finally, Moloney Securities Asset Management LLC boosted its position in OncoSec Medical by 117.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 27,000 shares during the last quarter. Hedge funds and other institutional investors own 6.38% of the company’s stock.

Shares of ONCS traded down $0.01 during mid-day trading on Friday, reaching $0.57. 473,168 shares of the company’s stock were exchanged, compared to its average volume of 633,565. OncoSec Medical has a 52-week low of $0.42 and a 52-week high of $1.96.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Read More: What Are Treasury Bonds?

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.